Combatting the evolution of antifungal resistance in Cryptococcus neoformans.
Cryptococcus neoformans
antifungal resistance
antifungals
antivirulence
fungal pathogenesis
Journal
Molecular microbiology
ISSN: 1365-2958
Titre abrégé: Mol Microbiol
Pays: England
ID NLM: 8712028
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
28
01
2020
revised:
09
06
2020
accepted:
22
06
2020
pubmed:
23
7
2020
medline:
24
8
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Fungal infections are a global concern and the evolution of intrinsic resistance to current antifungals presents an alarming problem. For Cryptococcus neoformans, a human fungal pathogen of primarily immunocompromised individuals, resistance toward treatment strategies demands alternative approaches. Given the prevalence of virulence factor production during cryptococcal infection, an emerging and important field of research encompasses the development of novel antivirulence therapies proposed to improve host immune responses and promote fungal clearance. To accomplish this task, information regarding the presence and role of virulence factors, the mechanisms of action within the host, and the ability to influence fungal susceptibility to antifungals is pertinent. Research into mechanisms of antifungal resistance for C. neoformans is limited but extrapolation from successful studies in other fungal species can improve our understanding of mechanisms employed by C. neoformans and suggest targeted strategies to enhance our ability to combat the pathogen. In this Review, we highlight antifungal therapy options against Cryptococcus, explore current knowledge of underlying mechanisms promoting resistance, and present new opportunities for novel and effective strategies to overcome fungal infections and reduce, or possibly even reverse, the effects of resistance evolution.
Substances chimiques
Antifungal Agents
0
Virulence Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-734Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Aberg, J.A., Price, R.W., Heeren, D.M. and Bredt, B. (2002) A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. Journal of Infectious Diseases, 185(8), 1179-1182. https://doi.org/10.1086/339680
Agnello, S., Brand, M., Chellat, M.F., Gazzola, S. and Riedl, R. (2019) A structural view on medicinal chemistry strategies against drug resistance. Angewandte Chemie - International Edition, 58(11), 3300-3345. https://doi.org/10.1002/anie.201802416
Almeida, F., Wolf, J.M. and Casadevall, A. (2015) Virulence-associated enzymes of Cryptococcus neoformans. Eukaryotic Cell, 14(12), 1173-1185. https://doi.org/10.1128/EC.00103-15
Alspaugh, J.A. (2015) Virulence mechanisms and Cryptococcus neoformans pathogenesis. Fungal Genetics and Biology, 78, 55-58. https://doi.org/10.1016/j.fgb.2014.09.004
Ambati, S., Ferarro, A.R., Kang, S.E., Lin, J., Lin, X., Momany, M., et al. (2019) Dectin-1-targeted antifungal liposomes exhibit enhanced efficacy. mSphere 4(1), e00025-19. https://doi.org/10.1128/msphere.00025-19
Ashu, E.E. and Jianping, X. (2018) Strengthening the one health agenda: the role of molecular epidemiology in Aspergillus threat management. Genes, 9(7), 359. https://doi.org/10.3390/genes9070359
Azevedo, R., Rizzo, J. and Rodrigues, M. (2016) Virulence factors as targets for anticryptococcal therapy. Journal of Fungi, 2(4), 29. https://doi.org/10.3390/jof2040029
Bahr, N.C., Rolfes, M.A., Musubire, A., Nabeta, H., Williams, D.A., Rhein, J., et al. (2014) Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infectious Diseases, 1(2), ofu070. https://doi.org/10.1093/ofid/ofu070
Bastos, R.W., Carneiro, H.C.S., Oliveira, L.V.N., Rocha, K.M., Freitas, G.J.C., Costa, M.C., et al. (2018) Environmental triazole induces cross-resistance to clinical drugs and affects morphophysiology and virulence of Cryptococcus gattii and C. neoformans. Antimicrobial Agents and Chemotherapy, 62(1), e01179-17. https://doi.org/10.1128/AAC.01179-17
Bennett, J.E., Dismukes, W.E., Duma, R.J., Medoff, G., Sande, M.A., Gallis, H., et al. (1979) A comparison of amphotericin b alone and combined with flucytosine in the treatment of cryptococcal meningitis. New England Journal of Medicine, 301(3), 126-131. https://doi.org/10.1056/NEJM197907193010303
Bhattacharya, S., Esquivel, B.D. and White, T.C. (2018) Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae. mBio, 9(4), e01291-18. https://doi.org/10.1128/mBio.01291-18
Bicanic, T., Wood, R., Bekker, L.G., Darder, M., Meintjes, G. and Harrison, T.S. (2005) Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infectious Diseases, 5(9), 530-531. https://doi.org/10.1016/S1473-3099(05)70197-3
Billmyre, R., Clancey, S., Li, L., Doering, T. and Heitman, J. (2020) 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nature Communications, 11(1), 1-9.
Bloom, A.L.M., Jin, R.M., Leipheimer, J., Bard, J.E., Yergeau, D., Wohlfert, E.A., et al. (2019) Thermotolerance in the pathogen Cryptococcus neoformans is linked to antigen masking via mRNA decay-dependent reprogramming. Nature Communications, 10(1), 1-13. https://doi.org/10.1038/s41467-019-12907-x
Bongomin, F., Gago, S., Oladele, R. and Denning, D. (2017) Global and multi-national prevalence of fungal diseases-estimate precision. Journal of Fungi, 3(4), 57. https://doi.org/10.3390/jof3040057
Bosco-Borgeat, M.E., Mazza, M., Taverna, C.G., Córdoba, S., Murisengo, O.A., Vivot, W., et al. (2016) Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates. Revista Argentina de Microbiologia, 48(2), 137-142. https://doi.org/10.1016/j.ram.2016.03.003
Brammer, K.W., Farrow, P.R. and Faulkner, J.K. (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Reviews of Infectious Diseases, 12(Supplement 3), S318-S326. https://doi.org/10.1093/clinids/12.Supplement_3.S318
Brandt, M.E., Pfaller, M.A., Hajjeh, R.A., Hamill, R.J., Pappas, P.G., Reingold, A.L., et al. (2001) Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrobial Agents and Chemotherapy, 45(11), 3065-3069. https://doi.org/10.1128/AAC.45.11.3065-3069.2001
Brouwer, A.E., Rajanuwong, A., Chierakul, W., Griffin, G.E., Larsen, R.A., White, N.J., et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet, 363(9423), 1764-1767. https://doi.org/10.1016/S0140-6736(04)16301-0
Casadevall, A., Coelho, C., Cordero, R.J., Dragotakes, Q., Jung, E., Vij, R., et al. (2019) The capsule of Cryptococcus neoformans. Virulence, 10(1), 822-831. https://doi.org/10.1080/21505594.2018.1431087
Castanheira, M., Deshpande, L.M., Davis, A.P., Rhomberg, P.R. and Pfaller, M.A. (2017) Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 61(10), e00906-17. https://doi.org/10.1128/AAC.00906-17
Chandenier, J., Adou-Bryn, K. D., Douchet, C., Sar, B., Kombila, M., Swinne, D., et al. (2004) In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans from Africa and Cambodia. European Journal of Clinical Microbiology and Infectious Diseases, 23(6), 506-508. https://doi.org/10.1007/s10096-004-1136-2
Chang, Y.C., Stins, M.F., McCaffery, M.J., Miller, G.F., Pare, D.R., Dam, T., et al. (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infection and Immunity, 72(9), 4985-4995. https://doi.org/10.1128/IAI.72.9.4985-4995.2004
Chang, Y.C., Jong, A., Huang, S., Zerfas, P. and Kwon-Chung, K.J. (2006) CPS1, a homolog of the Streptococcus pneumoniae type 3 polysaccharide synthase gene, is important for the pathobiology of Cryptococcus neoformans. Infection and Immunity, 74(7), 3930-3938. https://doi.org/10.1128/IAI.00089-06
Chen, Y.C., Chang, T.Y., Liu, J.W., Chen, F.J., Chien, C.C., Lee, C.H., et al. (2015) Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: A 12-year longitudinal study. BMC Infectious Diseases, 15(1), 277. https://doi.org/10.1186/s12879-015-1023-8
Cuenca-Estrella, M., Díaz-Guerra, T.M., Mellado, E. and Rodríguez-Tudela, J.L. (2001) Flucytosine primary resistance in candida species and Cryptococcus neoformans. European Journal of Clinical Microbiology and Infectious Diseases, 20(4), 276-279. https://doi.org/10.1007/s100960100468
Day, J.N., Chau, T.T.H., Wolbers, M., Mai, P.P., Dung, N.T., Mai, N.H., et al. (2013) Combination antifungal therapy for cryptococcal meningitis. New England Journal of Medicine, 368(14), 1291-1302. https://doi.org/10.1056/NEJMoa1110404
Denning, D.W. (2003) Echinocandin antifungal drugs. The Lancet, 362(9390), 1142-1151. https://doi.org/10.1016/S0140-6736(03)14472-8
Diasio, R.B., Lakings, D.E. and Bennett, J.E. (1978) Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrobial Agents and Chemotherapy, 14(6), 903-908. https://doi.org/10.1128/AAC.14.6.903
Dong, K., You, M. and Xu, J. (2020) Genetic changes in experimental populations of a hybrid in the Cryptococcus neoformans species complex. Pathogens, 9(1), 3. https://doi.org/10.3390/pathogens9010003
Dromer, F. and Levitz, S.M. (2014) Invasion of Cryptococcus into the central nervous system. In Cryptococcus (pp. 465-471) . Available at:https://www.asmscience.org/content/book/10.1128/9781555816858.pref01.
Dromer, F., Bernede-Bauduin, C., Guillemot, D. and Lortholary, O. (2008) Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One, 3(8), e2870. https://doi.org/10.1371/journal.pone.0002870
Farnoud, A.M., Bryan, A.M., Kechichian, T., Luberto, C. and Del Poeta, M. (2015) The granuloma response controlling cryptococcosis in mice depends on the sphingosine kinase 1-sphingosine 1-phosphate pathway. Infection and Immunity, 83(7), 2705-2713. https://doi.org/10.1128/IAI.00056-15
Galanis, E. and MacDougall, L. (2010) Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerging Infectious Diseases, 16(2), 251. https://doi.org/10.3201/eid1602.090900
Geddes, J.M.H., Croll, D., Caza, M., Stoynov, N., Foster, L.J., Kronstad, J.W., et al. (2015) Secretome profiling of Cryptococcus neoformans reveals regulation of a subset of virulence-associated proteins and potential biomarkers by protein kinase A. BMC Microbiology, 15, 1-26.
Geddes, J.M.H., Caza, M., Croll, D., Stoynov, N., Foster, L.J. and Kronstad, J. W. (2016) Analysis of the protein kinase a-regulated proteome of Cryptococcus neoformans identifies a role for the ubiquitin-proteasome pathway in capsule formation. mBio, 7, 1-15.
Geddes-McAlister, J. and Shapiro, R.S. (2018) New pathogens, new tricks: emerging, drug-resistant fungal pathogens and future prospects for antifungal therapeutics. Annals of the New York Academy of Sciences, 1435(1), 57-78. https://doi.org/10.1111/nyas.13739
Ghannoum, M.A. and Rice, L.B. (1999) Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews, 12(4), 501-517. https://doi.org/10.1128/cmr.12.4.501
Global Action Fund for Fungal Infections. (n.d.). Available at: https://antifungalsavailability.org/countries.
Gray, K.C., Palacios, D.S., Dailey, I., Endo, M.M., Uno, B.E., Wilcock, B.C., et al. (2012) Amphotericin primarily kills yeast by simply binding ergosterol. Proceedings of the National Academy of Sciences of the United States of America, 109(7), 2234-2239. https://doi.org/10.1073/pnas.1117280109
Gusa, A., Williams, J.D., Cho, J.E., Averette, A.F., Sun, S., Shouse, E.M., et al. (2020) Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. Proceedings of the National Academy of Sciences of the United States of America, 117(18), 9973-9980. https://doi.org/10.1073/pnas.2001451117
Harris, J.R., Lockhart, S.R., Debess, E., Marsden-Haug, N., Goldoft, M., Wohrle, R., et al. (2011) Cryptococcus gattii in the united states: clinical aspects of infection with an emerging pathogen. Clinical Infectious Diseases, 53(12), 1188-1195. https://doi.org/10.1093/cid/cir723
Hope, W., Steen, B.R., Lian, T., Sham, A.P., Tam, N., Tangen, K.L., et al. (2019) Fluconazole monotherapy is a suboptimal option for initial treatment of cryptococcal meningitis because of emergence of resistance. mBio, 10, e2575-e2619.
Hope, W.W., Tabernero, L., Denning, D.W. and Anderson, M.J. (2004) Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrobial Agents and Chemotherapy, 48(11), 4377-4386. https://doi.org/10.1128/AAC.48.11.4377-4386.2004
Hu, G., Steen, B.R., Lian, T., Sham, A.P., Tam, N., Tangen, K.L., et al. (2007) Transcriptional regulation by protein kinase A in Cryptococcus neoformans. PLoS Pathogens, 3(3), e42. https://doi.org/10.1371/journal.ppat.0030042
Huang, S.H., Long, M., Wu, C. H., Kwon-Chung, K. J., Chang, Y. C., Chi, F., et al. (2011) Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). Journal of Biological Chemistry, 286(40), 34761-34769. https://doi.org/10.1074/jbc.M111.219378
Jong, A., Wu, C.H., Chen, H.M., Luo, F., Kwon-Chung, K.J., Chang, Y.C., et al. (2007) Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryotic Cell, 6(8), 1486-1496. https://doi.org/10.1128/EC.00120-07
Joseph-Horne, T., Loeffler, R.S.T., Hollomon, D.W. and Kelly, S.L. (1996) Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. Journal of Medical and Veterinary Mycology, 34(3), 223-225. https://doi.org/10.1080/02681219680000381
Kagan, S., Ickowicz, D., Shmuel, M., Altschuler, Y., Sionov, E., Pitusi, M., et al. (2012) Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan. Antimicrobial Agents and Chemotherapy, 56(11), 5603-5611. https://doi.org/10.1128/AAC.00612-12
Kamiński, D.M. (2014) Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. European Biophysics Journal, 43(10-11), 453-467. https://doi.org/10.1007/s00249-014-0983-8
Kapoor, M., Moloney, M., Soltow, Q.A., Pillar, C.M. and Shaw, K.J. (2020) Evaluation of resistance development to the GWT1 inhibitor manogepix (APX001A) in Candida species. Antimicrobial Agents and Chemotherapy, 64(1):e01387-19. https://doi.org/10.1128/AAC.01387-19
Kelly, S.L., Lamb, D. C., Taylor, M., Corran, A. J., Baldwin, B. C. and Powderly, W. G. (1994) Resistance to amphotericin B associated with defective sterol Δ8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiology Letters, 122(1-2), 39-42.https://doi.org/10.1111/j.1574-6968.1994.tb07140.x
Kelly, S.L., Lamb, D.C., Loeffler, J., Einsele, H. and Kelly, D.E. (1999) The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochemical and Biophysical Research Communications, 262(1), 174-179. https://doi.org/10.1006/bbrc.1999.1136
Klepser, M. (2011) The value of amphotericin B in the treatment of invasive fungal infections. Journal of Critical Care, 26(2), 225.e1-225.e10. https://doi.org/10.1016/j.jcrc.2010.08.005
Kneale, M., Bartholomew, J.S., Davies, E. and Denning, D.W. (2016) Global access to antifungal therapy and its variable cost. Journal of Antimicrobial Chemotherapy, 71(12), 3599-3606. https://doi.org/10.1093/jac/dkw325
Kronstad, J.W., Attarian, R., Cadieux, B., Choi, J., D'Souza, C.A., Griffiths, E.J., et al. (2011) Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nature Reviews Microbiology, 9(3), 193-203. https://doi.org/10.1038/nrmicro2522
Kugadas, A., Geddes-McAlister, J., Guy, E., DiGiandomenico, A., Sykes, D.B., Mansour, M.K., et al. (2019) Frontline science: employing enzymatic treatment options for management of ocular biofilm-based infections. Journal of Leukocyte Biology, 105(6), 1099-1110. https://doi.org/10.1002/JLB.4HI0918-364RR
Lamichhane, A.K., Garraffo, H.M., Cai, H., Walter, P.J., Kwon-Chung, K.J. and Chang, Y.C. (2019) A novel role of fungal type I myosin in regulating membrane properties and its association with d-amino acid utilization in Cryptococcus gattii. mBio, 10(4):e01867-19. https://doi.org/10.1128/mBio.01867-19
Lee, D., Jang, E.H., Lee, M., Kim, S.W., Lee, Y., Lee, K.T., et al. (2019) Unraveling melanin biosynthesis and signaling networks in Cryptococcus neoformans. mBio, 10(5):e02267-19. https://doi.org/10.1128/mBio.02267-19
Lepesheva, G.I., Hargrove, T.Y., Kleshchenko, Y., Nes, W.D., Villalta, F. and Waterman, M.R. (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids, 43(12), 1117-1125. https://doi.org/10.1007/s11745-008-3225-y
Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338. https://doi.org/10.1038/nrc1074
Loyse, A., Thangaraj, H., Easterbrook, P., Ford, N., Roy, M., Chiller, T., et al. (2013) Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. The Lancet Infectious Diseases, 13(7), 629-637. https://doi.org/10.1016/S1473-3099(13)70078-1
Martínez, E., García-Viejo, M.A., Marcos, M.A., Pérez-Cuevas, J.B., Blanco, J.L., Mallolas, J., et al. (2000) Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS, 14(16), 2615-2617. https://doi.org/10.1097/00002030-200011100-00029
Matsumoto, M., Ishida, K., Konagai, A., Maebashi, K. and Asaoka, T. (2002) Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi. Antimicrobial Agents and Chemotherapy, 46(2), 308-314. https://doi.org/10.1128/AAC.46.2.308-314.2002
May, L., Chretien, J.P. and Pavlin, J.A. (2009) Beyond traditional surveillance: applying syndromic surveillance to developing settings-opportunities and challenges. BMC Public Health, 9(1), 242. https://doi.org/10.1186/1471-2458-9-242
May, R.C., Stone, N.R.H., Wiesner, D.L., Bicanic, T. and Nielsen, K. (2016) Cryptococcus: from environmental saprophyte to global pathogen. Nature Reviews Microbiology, 14(2), 106-117. https://doi.org/10.1038/nrmicro.2015.6
Mayanja-Kizza, H., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K., et al. (1998) Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clinical Infectious Diseases, 26(6), 1362-1366. https://doi.org/10.1086/516372
Mayer, F.L. and Kronstad, J.W. (2017a) Discovery of a novel antifungal agent in the pathogen box. mSphere, 2(2), e00120-17. https://doi.org/10.1128/mSphere.00120-17
Mayer, F.L. and Kronstad, J.W. (2017) Disarming fungal pathogens: bacillus safensis inhibits virulence factor production and biofilm formation by Cryptococcus neoformans and Candida albicans. mBio, 8(5), e01537-17. https://doi.org/10.1128/mbio.01537-17
Mayers, D. (2009) Antimicrobial Drug Resistance Handbook, Vol. 1. Humana Press. https://www.springer.com/gp/book/9781603275927.
McKenney, J., Bauman, S., Neary, B., Detels, R., French, A., Margolick, J., et al. (2015) Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012. Clinical Infectious Diseases, 60(6), 959-965. https://doi.org/10.1093/cid/ciu937
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., et al. (1999) Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 43(8), 1856-1861. https://doi.org/10.1128/aac.43.8.1856
Mourad, A. and Perfect, J.R. (2018) Present and future therapy of Cryptococcus infections. Journal of Fungi, 4(3), 79. https://doi.org/10.3390/jof4030079
Mouri, R., Konoki, K., Matsumori, N., Oishi, T. and Murata, M. (2008) Complex formation of amphotericin B in sterol-containing membranes as evidenced by surface plasmon resonance. Biochemistry, 47(30), 7807-7815. https://doi.org/10.1021/bi800334p
Mussini, C., Pezzotti, P., Miro, J.M., Martinez, E., de Quiros, J.C.L.B., Cinque, P., et al. (2004) Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clinical Infectious Diseases, 38(4), 565-571. https://doi.org/10.1086/381261
Nosanchuk, J.D., Stark, R.E. and Casadevall, A. (2015) Fungal melanin: what do we know about structure? Frontiers in Microbiology, 6, 1463. https://doi.org/10.3389/fmicb.2015.01463
Nussbaum, J.C., Jackson, A., Namarika, D., Phulusa, J., Kenala, J., Kanyemba, C., et al. (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clinical Infectious Diseases, 50(3), 338-344. https://doi.org/10.1086/649861
O’Meara, T.R. and Andrew Alspaugh, J. (2012) The Cryptococcus neoformans capsule: a sword and a shield. Clinical Microbiology Reviews, 25(3), 387-408. https://doi.org/10.1128/CMR.00001-12
Oladele, R.O., Bongomin, F., Gago, S. and Denning, D.W. (2017) HIV-associated cryptococcal disease in resource-limited settings: a case for “prevention is better than cure”? Journal of Fungi, 3(4), 67. https://doi.org/10.3390/jof3040067
Olszewski, M.A., Noverr, M.C., Chen, G.H. Toews, G.B., Cox, G.M., Perfect, J.R., et al. (2004) Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. American Journal of Pathology, 164(5), 1761-1771. https://doi.org/10.1016/S0002-9440(10)63734-0
Papon, N., Noël, T., Florent, M., Gibot-Leclerc, S., Jean, D., Chastin, C., et al. (2007) Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrobial Agents and Chemotherapy, 51(1), 369-371. https://doi.org/10.1128/AAC.00824-06
Parker, J.E., Merkamm, M., Manning, N.J., Pompon, D., Kelly, S.l. and Kelly, D.E. (2008) Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14α-demethylase at the homologous locus. Antimicrobial Agents and Chemotherapy, 52(10), 3597-3603. https://doi.org/10.1128/AAC.00517-08
Perfect, J.R. (2017) The antifungal pipeline: a reality check. Nature Reviews Drug Discovery, 16(9), 603-616. https://doi.org/10.1038/nrd.2017.46
Perfect, J.R., Dismukes, W.E., Dromer, F., Goldman, D.L., Graybill, J.R., Hamill, R.J., et al. (2018) Guideline for cryptococcus. Clinical Infectious Diseases, 50, 291-322.
Perfect, J.R. and Cox, G.M. (1999) Drug resistance in Cryptococcus neoformans. Drug Resistance Updates, 2(4), 259-269. https://doi.org/10.1054/drup.1999.0090
Perlin, D.S. (2015) Mechanisms of echinocandin antifungal drug resistance. Annals of the New York Academy of Sciences, 1354(1), 1. https://doi.org/10.1111/nyas.12831
Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Bijie, H., Dzierzanowska, D., et al. (2009) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. Journal of Clinical Microbiology, 47(1), 117-123. https://doi.org/10.1128/JCM.01747-08
Pfaller, M.A., Diekema, D.J., Turnidge, J.D., Castanheira, M. and Jones, R.N. (2019) Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infectious Diseases, 6(Supplement 1), S79-S94. https://doi.org/10.1093/ofid/ofy358
Polak, A. and Scholer, H.J. (1975) Mode of action of 5 fluorocytosine and mechanisms of resistance. Chemotherapy, 21(3-4), 113-130. https://doi.org/10.1159/000221854
Powderly, W.G., Saag, M.S., Cloud, G.A., Robinson, P., Meyer, R.D., Jacobson, J.M., et al. (1992) A controlled trial of fluconazole or amphotericin b to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine, 326(12), 793-798. https://doi.org/10.1056/NEJM199203193261203
Rajasingham, R., Smith, R.M., Park, B.J., Jarvis, J.N., Govender, N.P., Chiller, T.M., et al. (2017) Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. The Lancet Infectious Diseases, 17(8), 873-881. https://doi.org/10.1016/S1473-3099(17)30243-8
Rhodes, J., Beale, M.A., Vanhove, M., Jarvis, J.N., Kannambath, S., Simpson, J.A., et al. (2017) A population genomics approach to assessing the genetic basis of within-host microevolution underlying recurrent cryptococcal meningitis infection. G3 Genes|Genomes|Genetics, 7(4), 1165-1176. https://doi.org/10.1534/g3.116.037499
Rodero, L., Mellado, E., Rodriguez, A.C., Salve, A., Guelfand, L., Cahn, P., et al. (2003) G484S amino acid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrobial Agents and Chemotherapy, 47(11), 3653-3656. https://doi.org/10.1128/AAC.47.11.3653-3656.2003
Roemer, T. and Krysan, D.J. (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harbor Perspectives in Medicine, 4(5), a019703. https://doi.org/10.1101/cshperspect.a019703
Rosas, Á.L., Nosanchuk, J.D. and Casadevall, A. (2001) Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infection and Immunity, 69(5), 3410-3412. https://doi.org/10.1128/IAI.69.5.3410-3412.2001
Saag, M.S., Powderly, W.G., Cloud, G.A., Robinson, P., Grieco, M.H., Sharkey, P.K., et al. (1992) Comparison of amphotericin b with fluconazole in the treatment of acute aids-associated cryptococcal meningitis. New England Journal of Medicine, 326(2), 83-89. https://doi.org/10.1056/NEJM199201093260202
Sagatova, A.A., Keniya, M.V., Wilson, R.K., Sabherwal, M., Tyndall, J.D.A. and Monk, B.C. (2016) Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase. Scientific Reports, 6(1), e26213. https://doi.org/10.1038/srep26213
Samarasinghe, H., You, M., Jenkinson, T.S., Xu, J. and James, T.Y. (2020) Hybridization facilitates adaptive evolution in two major fungal pathogens. Genes, 11(1), 101. https://doi.org/10.3390/genes11010101
Sanglard, D. (2016) Emerging threats in antifungal-resistant fungal pathogens. Frontiers in Medicine, 3, e11. https://doi.org/10.3389/fmed.2016.00011
Sanglard, D., Ischer, F., Koymans, L. and Bille, J. (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14α- demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and Chemotherapy, 42(2), 241-253. https://doi.org/10.1128/aac.42.2.241
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D. and Bille, J. (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrobial Agents and Chemotherapy, 47(8), 2404-2412. https://doi.org/10.1128/AAC.47.8.2404-2412.2003
Santiago-Tirado, F.H., Onken, M.D., Cooper, J.A., Klein, R.S. and Doering, T.L. (2017) Trojan horse transit contributes to blood-brain barrier crossing of a eukaryotic pathogen. mBio, 8(1), e02183-16. https://doi.org/10.1128/mBio.02183-16
Schwarz, P., Dromer, F., Lortholary, O. and Dannaoui, E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy, 47(10), 3361-3364. https://doi.org/10.1128/AAC.47.10.3361-3364.2003
Schwarz, P., Dromer, F., Lortholary, O. and Dannaoui, E. (2006) Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrobial Agents and Chemotherapy, 50(1), 113-120. https://doi.org/10.1128/AAC.50.1.113-120.2006
Schwarz, P., Janbon, G., Dromer, F., Lortholary, O. and Dannaoui, E. (2007) Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 51(1), 383-385. https://doi.org/10.1128/AAC.00446-06
Shears, P. (2001) Epidemiology and surveillance of antimicrobial resistance in the tropics. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95(2), 127-130. https://doi.org/10.1016/S0035-9203(01)90134-8
Sheehan, D.J., Hitchcock, C.A. and Sibley, C.M. (1999) Current and emerging azole antifungal agents. Clinical Microbiology Reviews, 12(1), 40-79. https://doi.org/10.1128/cmr.12.1.40
Shi, M., Li, S.S., Zheng, C., Jones, G.J., Kim, K.S., Zhou, H., et al. (2010) Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. Journal of Clinical Investigation, 120(5), 1683-1693. https://doi.org/10.1172/JCI41963
Shourian, M. and Qureshi, S.T. (2019) Resistance and tolerance to cryptococcal infection: an intricate balance that controls the development of disease. Frontiers in Immunology, 10, e66. https://doi.org/10.3389/fimmu.2019.00066
Sionov, E., Chang, Y.C., Garraffo, H.M., Dolan, M.A., Ghannoum, M.A. and Kwon-Chung, K.J. (2012) Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrobial Agents and Chemotherapy, 56(3), 1162-1169. https://doi.org/10.1128/AAC.05502-11
Smith, K.D., Achan, B., Hullsiek, K.H., McDonald, T.R., Okagaki, L.H., Alhadab, A.A., et al. (2015) Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrobial Agents and Chemotherapy, 59(12), 7197-7204. https://doi.org/10.1128/AAC.01299-15
Specht, C.A., Lee, C.K., Huang, H., Hester, M.M., Liu, J., Luckie, B.A., et al. (2017) Vaccination with recombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and cryptococcal species. mBio, 8(6), e01872-17. https://doi.org/10.1128/mBio.01872-17
Srichatrapimuk, S. and Sungkanuparph, S. (2016) Integrated therapy for HIV and cryptococcosis. AIDS Research and Therapy, 13(1), 42. https://doi.org/10.1186/s12981-016-0126-7
Stone, N.R.H., Rhodes, J., Fisher, M.C., Mfinanga, S., Kivuyo, S., Rugemalila, J., et al. (2019) Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. Journal of Clinical Investigation, 129(3), 999-1014. https://doi.org/10.1172/JCI124516
Su, H., Han, L. and Huang, X. (2018) Potential targets for the development of new antifungal drugs. Journal of Antibiotics, 71(12), 978-991. https://doi.org/10.1038/s41429-018-0100-9
Sudan, A., Livermore, J., Howard, S.J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., et al. (2013) Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrobial Agents and Chemotherapy, 57(6), 2793-2800.https://doi.org/10.1128/AAC.00216-13
Tenforde, M.W., Mokomane, M., Leeme, T., Patel, R.K.K., Lekwape, N., Ramodimoosi, C., et al. (2017) Advanced human immunodeficiency virus disease in Botswana following successful antiretroviral therapy rollout: incidence of and temporal trends in cryptococcal meningitis. Clinical Infectious Diseases, 65(5), 779-786. https://doi.org/10.1093/cid/cix430
Trevinõ-Rangel, R.D.J., Villanueva-Lozano, H., Hernández-Rodríguez, P., Martínez-Reséndez, M. F., García-Juárez, J., Rodríguez-Rocha, H., et al. (2016) Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Medical Mycology, 54(3), 280-286. https://doi.org/10.1093/mmy/myv109
Umemura, M., Okamoto, M., Nakayama, K. I., Sagane, K., Tsukahara, K., & Hata, K., et al. (2003) GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. Journal of Biological Chemistry, 278(26), 23639-23647. https://doi.org/10.1074/jbc.M301044200
Upadhya, R., Lam, W.C., Maybruck, B., Specht, C.A., Levitz, S.M. and Lodge, J. K. (2016) Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans. mBio, 7(3), e00547-16. https://doi.org/10.1128/mBio.00547-16
Van Der Horst, C.M., Saag, M.S., Cloud, G.A., Hamill, R.J., Graybill, J.R., Sobel, J.D., et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. New England Journal of Medicine, 337(1), 15-21. https://doi.org/10.1056/NEJM199707033370103
Varma, A. and Kwon-Chung, K.J. (2010) Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrobial Agents and Chemotherapy, 54(6), 2303-2311. https://doi.org/10.1128/AAC.00153-10
Vermes, A., Van Der Sijs, H. and Guchelaar, H.J. (2000) Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy, 46(2), 86-94. https://doi.org/10.1159/000007260
Viriyakosol, S., Kapoor, M., Okamoto, S., Covel, J., Soltow, Q. A., Trzoss, M., et al. (2019) APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia. Antimicrobial Agents and Chemotherapy, 63(2), e01715-18.https://doi.org/10.1128/AAC.01715-18
Vogan, A.A., Khankhet, J., Samarasinghe, H. and Xu, J. (2016) Identification of QTLs associated with virulence related traits and drug resistance in Cryptococcus neoformans. G3: Genes, Genomes, Genetics, 6(9), 2745-2759. https://doi.org/10.1534/g3.116.029595
Vu, K., Tham, R., Uhrig, J.P., Thompson, G.R., Na Pombejra, S., Jamklang, M., et al. (2014) Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. mBio, 5(3), e01101-14. https://doi.org/10.1128/mBio.01101-14
Vu, K., Thompson, G.R., Roe, C.C., Sykes, J.E., Dreibe, E.M., Lockhart, S.R., et al. (2018) Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway. Medical Mycology, 56(7), 857-867. https://doi.org/10.1093/mmy/myx135
Vu, K., Garcia, J.A. and Gelli, A. (2019) Cryptococcal meningitis and antivirulence therapeutic strategies. Frontiers in Microbiology, 10, 353. https://doi.org/10.3389/fmicb.2019.00353
Waldorf, A.R. and Polak, A. (1983) Mechanisms of action of 5-fluorocytosine. Antimicrobial Agents and Chemotherapy, 23(1), 79-85. https://doi.org/10.1128/AAC.23.1.79
Warrilow, A.G., Parker, J.E., Kelly, D.E. and Kelly, S.L. (2013) Azole affinity of sterol 14-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrobial Agents and Chemotherapy, 57(3), 1352-1360. https://doi.org/10.1128/AAC.02067-12
Wiederhold, N.P. (2017) Antifungal resistance: current trends and future strategies to combat. Infection and Drug Resistance, 10, 249. https://doi.org/10.2147/IDR.S124918
Williamson, P.R., Jarvis, J.N., Panackal, A.A., Fisher, M.C., Molloy, S.F., Loyse, A., et al. (2016) Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nature Reviews Neurology, 13(1), 13-24. https://doi.org/10.1038/nrneurol.2016.167
Yang, D.H., Jung, K.W., Bang, S., Lee, J.W., Song, M.H., Floyd-Averette, A., et al. (2017) Rewiring of signaling networks modulating thermotolerance in the human pathogen Cryptococcus neoformans. Genetics, 205(1), 201-219. https://doi.org/10.1534/genetics.116.190595
Yeo, E.J., Ryu, J.H., Cho, Y.S., Chun, Y.S., Huang, L.E., Kim, M.S., et al. (2006) Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood, 107(3), 916-923. https://doi.org/10.1182/blood-2005-06-2564
Yu, Y., Peng, L., Liao, G., Chen, Z. and Li, C. (2019) Noncovalent complexation of amphotericin B with poly(β-Amino Ester) derivates for treatment of C. neoformans infection. Polymers, 11(2), 270. https://doi.org/10.3390/polym11020270
Zaragoza, O. (2019) Basic principles of the virulence of Cryptococcus. Virulence, 10(1), 490-501. https://doi.org/10.1080/21505594.2019.1614383
Zhai, B., Wu, C., Wang, L., Sachs, M.S. and Lin, X. (2012) The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrobial Agents and Chemotherapy, 56(7), 3758-3766. https://doi.org/10.1128/AAC.00212-12